Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024Investors Business Daily • 01/05/24
Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 01/04/24
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 12/29/23
Biogen ‘welcomes' EC decision to revoke CMAs for generic versions of TecfideraMarket Watch • 12/19/23
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionGlobeNewsWire • 12/19/23
CHMP Issues Positive Opinion for Biogen's SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative DiseaseGlobeNewsWire • 12/15/23
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.Business Wire • 12/14/23
Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)Seeking Alpha • 11/28/23
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?The Motley Fool • 11/10/23
Biogen lowers full-year earnings guidance, 3Q revenue beats expectationsProactive Investors • 11/08/23
Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/08/23